Recently, we demonstrated that the presence of high percentages of activated cytotoxic T-lymphocytes (CTLs) in biopsy specimens of both Hodgkin's disease (HD) and ALK negative anaplastic large cell lymphoma (ALCL) is associated with a poor prognosis. To test whether this biological prognostic factor is more important in predicting clinical outcome than histological diagnosis or clinical factors, we compared the prognostic value of these parameters in an expanded group of classical HD and ALK negative ALCL. Tumor biopsies of classical HD (n = 83) and ALK negative systemic nodal ALCL (n = 43) were investigated for the presence of activated CTLs by immunohistochemistry, using a monoclonal antibody directed against granzyme B. Percentages of activated CTLs were quantified using Q-PRODIT, and their prognostic value was compared to that of histological diagnosis and clinical parameters, including age and stage. Both in classical HD and ALK negative ALCL, a high percentage of activated CTLs (ie у15%) identified a group of patients with poor overall and progression-free survival time, even when adjusted for stage. In multivariate analysis, percentage of activated CTLs remained a strong independent prognostic marker, and was more sensitive than histological diagnosis or clinical factors in predicting overall survival time. We conclude that a high percentage of activated CTLs in the reactive infiltrate of ALK negative ALCL and classical HD is a strong indicator for an unfavorable clinical outcome, regardless of histological diagnosis or clinical parameters. As such, this biological parameter may be an especially helpful tool to determine therapeutic strategies in cases in which the differentiation between ALK negative ALCL and HD remains difficult. Leukemia (2001) 15, 458-464. 
Introduction
Systemic nodal anaplastic large cell lymphoma (ALCL) is a subgroup of T-non-Hodgkin's lymphomas, characterized by tumor cells with abundant cytoplasm, large irregular nuclei, and single or multiple nucleoli. They arise in a background of small lymphocytes, and show expression of CD30, a member of the tumor necrosis factor (TNF) family. 1 Thirty to 60% of systemic nodal ALCL show aberrant expression of the anaplastic lymphoma kinase (ALK) protein, usually due to a t(2;5)(p23;q35), which fuses the ALK gene at 2p23 with the nucleophosmin (NPM) gene at 5q35. 2 These ALK positive ALCL cases are generally characterized by an excellent prognosis. [3] [4] [5] [6] ALK expression seems specific for systemic nodal ALCL; 7 it is not found in classical Hodgkin's disease (HD), [8] [9] [10] [11] [12] a CD30 positive disease entity that may closely resemble ALCL. Clinically, however, HD is characterized by a very favorable prognosis as compared to ALK negative ALCL. HD patients show a 5-year survival of approximately 85%, 13 whereas (less than) 50% of ALK negative ALCL patients are still alive after 5 years. [3] [4] [5] In the treatment of these lymphomas, ALCL usually requires more intensive therapy than HD.
14 Because of the differences in clinical behavior and subsequent therapeutic strategies, differentiating between ALK negative ALCL and HD is very important.
Recently, we identified a strong prognostic marker for ALK negative ALCL. A high percentage of activated CTLs present in the reactive infiltrate of nodal ALCL was found to be related to a very poor prognosis. 4 This biological prognostic parameter, combined with ALK status, seemed as sensitive or even more sensitive than the established International Prognostic Index, 15 which comprises five clinical prognostic factors. The same relationship between clinical outcome and numbers of activated CTLs had been shown before for HD. 16 These results led to the notion that in some cases not the histological diagnosis (ALCL vs HD), but rather the immune response against tumor cells determines clinical outcome. In the present study, we tested this hypothesis by expanding our cases of ALCL and classical HD, and investigating the prognostic value of the number of activated CTLs in comparison to the histological diagnosis, as well as clinical parameters including stage and age at presentation.
Materials and methods

Patient selection
From the files of the Comprehensive Cancer Centre Amsterdam, from the Department of Pathology, Rijnstate Hospital, Arnhem, and from the Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands, we selected primary diagnostic tumor biopsies of ALK negative systemic nodal ALCL (n = 43) and (nodal) classical HD (n = 83). ALK positive ALCL were excluded from the study, as this subtype of ALCL has been found to show excellent prognosis, [3] [4] [5] [6] irrespective of the percentage of activated CTLs. 4 Some of the cases used in this study have already been described by us in previous studies. 4, 16 Cases were classified according to the REAL/WHO classification 1, 17 by a panel of expert hematopathologists; identifying ALCL as a proliferation of CD30
+ blastic cells with a T cell or null-cell phenotype, lying either in cohesive sheets and/or intrasinusoidal; whereas classical HD was identified by the presence of scattered CD30
+ blasts with the typical Reed-Sternberg or Hodgkin cell appearance. Additional immunophenotyping included CD15 and epithelial membrane antigen (EMA) as markers for HD and ALCL, respectively. Not included in the analysis were an additional nine cases, in which the differential diagnosis between HD and ALCL posed a problem. An overview of these nine 'grey zone' cases is given in Table 1 .
Our criteria allowed for the inclusion of several subtypes of ALCL as described by others, 18, 19 namely: common type ALCL (n = 27; 63%); lymphohistiocytic type (n = 8; 19%), mixed (lymphohistiocytic and giant cell rich) type (n = 1; 2%), small cell variant (n = 3; 7%), and giant cell rich variant (n = 4; 9%). The HD cases belonged to either the nodular sclerosis subtype (n = 71; 86%) or the mixed cellularity subtype (n = 12; 14%).
Detection of activated cytotoxic T-cells
At present, accurate detection of activated CTLs is possible using the monoclonal antibody GB7, which reacts specifically with granzyme B (GrB).
20,21
Immunohistochemistry was performed as described previously, using a three-step staining technique. 20, 21 Additional double staining demonstrated that the large majority of GrB + reactive lymphocytes are also positive for CD3 and CD8, and are thus in majority activated CTLs.
Quantification of the percentage of activated CTLs in the reactive infiltrate was performed using a commercially available interactive video overlay-based measuring system (Q-PRODIT, Leica, Cambridge, UK), as described previously. 4, 16 Per tumor slide, 100-150 fields of vision were randomly selected using an automatic scanning stage. Numbers of GrB + lymphocytes were expressed as percentages of all lymphocytes present in a tissue section as judged by morphologic criteria. As described in a previous paper, 4 in a minority of ALCL cases (n = 4) we used a double staining method to differentiate between (GrB 
Analysis of clinical data
Where available, the following characteristics were noted from the medical records of each patient: age at diagnosis, sex, Ann Arbor stage at presentation, therapy, response, the occurrence of relapses, and cause of death. For ALK negative ALCL the International Prognostic Index (IPI) was determined as described previously. 15 Therapy in both patient groups consisted of polychemotherapy with or without involved field radiation; ALCL patients receiving CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimens or variants, whereas HD patients received MOPP (mechlorethamine, oncovin, procarbazine, prednisone) regimens or variants. Stage 1 patients were usually treated with radiotherapy alone.
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The median follow-up time was 20 months (range 0 to 207 months) for ALK negative ALCL, and 71 months (range 0-174 months) for the HD cases. Survival time was measured from time of initial diagnosis until death due to disease or until end of follow-up. Patients who died of causes unrelated to the disease were censored at the time of death. Progression-free survival time was measured from time of initial diagnosis until time of disease relapse. Patients who did not enter complete remission were assigned a progression-free survival time of zero in the analysis.
Statistical methods
Survival curves were constructed with the Kaplan-Meier method. Differences between the curves were analyzed using the log-rank test. Multivariate analysis was performed using the Cox-proportional hazards model (enter and remove limits 0.1). Comparison of means was performed using the Student's t-test. Qualitative variables were analyzed by Pearson 2 test or by the Fisher exact test, when appropriate. All P values are based on two-tailed statistical analysis, and P values below 0.05 were considered as significant. All analyses were performed using the SPSS statistical software (SPSS, Chicago, IL, USA).
Results
Granzyme B expression
In all cases tested, GrB + reactive lymphocytes (ie activated CTLs) were found interspersed between the tumor cells, and displaying a granular cytoplasmic staining pattern, which reflects the granular localization of GrB (Figure 1 ). In HD, numbers of activated CTLs ranged between 1 and 38% of reactive lymphocytes, with 11/83 cases (13%) showing more than 15% activated CTLs. In ALK negative ALCL, numbers of activated CTLs ranged between 1 and 62%, with 25/43 cases (58%) containing more than 15% activated CTLs.
GrB expression by tumor cells was found in 20 of 43 ALK negative ALCL (46.5%), with the percentage of GrB + tumor cells ranging from a few to more than 90% of tumor cells. 
Prognostic value of histological diagnosis and clinical parameters
In univariate analysis, histological diagnosis (ALK negative ALCL vs classical HD) was strongly predictive of overall survival time (Figure 2) . Of the HD patients, only 12 (14%) died as a result of the disease, compared to 25 (58%) of ALK negative ALCL patients (P Ͻ 0.0001). The 5-year survival was approximately 85% for classical HD and 45% for ALK negative ALCL.
For HD patients, prognosis declined with increasing age (P Ͻ 0.0001) and advanced stages of disease (P Ͻ 0.05). The IPI, comprising five clinical parameters including age and stage, was predictive of prognosis in ALK negative ALCL (P Ͻ 0.01).
Prognostic value of percentage activated CTLs
The influence of the percentage of activated CTLs on overall survival time was estimated by Cox regression analysis. In both HD and ALK negative ALCL, the prognosis was found to decline with increasing percentages of activated CTLs (entered as a continuous variable).
If the patients (in ALK negative ALCL and HD each) were divided into a group with у15% or Ͻ15% activated CTLs (the threshold leading to the lowest P-value), the presence of Comparison of overall survival time, according to diagnosis (ALCL vs nodular sclerosis and mixed cellularity HD) and ALK expression.
у15% activated CTLs defined a group of patients with an unfavorable prognosis. Patient and tumor characteristics according to percentage activated CTLs and histological diagnosis are summarized in Table 2 .
Six out of 11 HD patients with у15% activated CTLs died as a result of the disease, compared to 6/72 HD patients with Ͻ15% activated CTLs ( Figure 3 ) (P Ͻ 0.0001, adjusted for stage: P Ͻ 0.0001). The progression-free survival time was significantly shortened in HD cases with у15% activated CTLs ( Figure 4 ) (P = 0.0025, adjusted for stage: P = 0.0016). In ALK negative ALCL, a similar effect was found: 21/25 patients with у15% activated CTLs died as a result of the disease, compared to 4/18 patients with Ͻ15% activated CTLs ( Figure 3 ) (P = 0.0001, adjusted for stage: P = 0.0005). ALK negative ALCL patients with у15% activated CTLs also had a significantly shortened progression-free survival time ( Figure 4 ) (P Ͻ 0.01, adjusted for stage: P Ͻ 0.05).
As shown in Table 2 , cases with у15% activated CTLs in both HD and ALCL presented with less favorable clinical features, such as older age, advanced stage of disease, infrequent complete remission and frequent relapses, as compared to cases with Ͻ15% activated CTLs. Five-year survival was р40% for cases with у15% activated CTLs, compared to у80% 5-year survival in cases with Ͻ15% activated CTLs. The relationship between poor clinical features and a high percentage of activated CTLs was irrespective of histological diagnosis (see note to Table 2 ). In the group with Ͻ15% activated CTLs, classical HD patients were significantly younger and showed a better 5-year survival than ALK negative ALCL patients.
Multivariate analysis of overall survival time
Classical HD and ALK negative ALCL were combined, and a multivariate analysis of overall survival time was performed, using the Cox-proportional hazards model. Variables included were percentage of activated CTLs and age (entered as a continuous variable), stage, and histological diagnosis (ALCL vs HD). All variables, including percentage of activated CTLs, remained independent prognostic parameters, with percentage of activated CTLs as the strongest prognosticator. When comparing only cases with у15% activated CTLs, differences between ALCL (c) and HD (d) patients were not significant for any of the characteristics. When comparing only cases with Ͻ15% activated CTLs, HD patients (b) were younger than ALCL patients (a) (P Ͻ 0.001), and showed better 5-year survival than ALCL patients (P Ͻ 0.05), although they did not significantly differ with regard to other characteristics.
Figure 3
Comparison of overall survival time and HD and ALK negative ALCL, according to percentage activated CTLs.
Discussion
Previously, we have shown that a high percentage (ie у15%) of activated CTLs in the reactive infiltrate of tumor biopsies is strongly related to poor prognosis, both in HD 16 and ALK negative ALCL. 4 In the present study, we show that in a multivariate analysis of overall survival time, the percentage of activated CTLs remains a strong prognosticator in a combined group of classical HD and ALK negative ALCL, independent of histological diagnosis and clinical parameters such as age and stage.
Classical HD and ALK negative ALCL are separate disease entities with different clinical behavior. 1, 17 In line with the literature, 13 the present study shows that HD has an excellent 5-year survival compared to ALK negative ALCL. However, since they also share many similarities with regard to morphology and immunophenotype, in some instances the initial diagnosis and subsequent therapeutic strategy may pose a problem. Recent studies have shown that the majority of Reed-Sternberg and Hodgkin cells are most likely derived
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Figure 4
Comparison of progression-free survival time in HD and ALK negtive ALCL, according to percentage activated CTLs. from B cells, [22] [23] [24] whereas ALCL are considered to be T cell lymphomas. 1, 17, [25] [26] [27] Still, in rare cases HD may be T cellderived. 28, 29 Thus, tumor cell lineage determination is not absolutely conclusive for the differential diagnosis between HD and ALK negative ALCL. Moreover, our finding that the percentage of activated CTLs remains a prognostic marker, independent of histological diagnosis, suggests that the interaction between CTLs and tumor cells (be they T or B cell derived) is a common pathogenic mechanism, more important for clinical outcome than lineage derivation.
Several markers may be helpful in the (differential) diagnosis of HD and ALK negative ALCL, namely CD15, EMA, the cytotoxic markers GrB and T cell intracytoplasmic antigen (TIA)-1, and Epstein-Barr virus (EBV). CD15 is usually expressed in 70-80% of HD, but in less than 30% of ALCL. [30] [31] [32] [33] Conversely, EMA expression is found in only a minority (Ͻ5%) of HD, but in 60-80% of ALCL. 30, 31, [33] [34] [35] [36] Recent studies have shown that the high expression of EMA in ALCL is largely attributable to the ALK positive cases, and only to a lesser extent found in ALK negative cases. 19, [37] [38] [39] The same strong association exists between (ALK positive) ALCL and the cytotoxic proteins GrB and TIA-1; 25, [39] [40] [41] proteins which are expressed in only a minority of HD. 25, 41, 42 EBV is found in approximately 40% of HD 43 and in 0-30% of ALCL, depending on the detection method used and the age of patients. 37, 38, [44] [45] [46] [47] [48] Thus, a CD15 Our finding that the percentage of activated CTLs is strongly related to clinical outcome, independently of clinical characteristics or histological diagnosis, may help to determine therapeutic strategies. It could be argued that in cases where the differential diagnosis between classical HD and ALK negative ALCL remains a problem, lymphomas presenting with у15% activated CTLs should be treated as non-Hodgkin's lymphomas. Similarly, it could be argued that even in the absence of 'classical' poor prognostic factors, lymphomas with у15% activated CTLs should be included in high risk treatment protocols.
As mentioned in Materials and methods, we excluded from the present study nine cases in which the differential diagnosis between HD and ALK negative ALCL remained unsolved (Table 1) . In these cases, a high percentage (у15%) of activated CTLs tended also to be related to shortened overall survival time (data not shown). However, the numbers are too low to draw definite conclusions, and studies comprising larger numbers are needed to clarify the prognostic value of activated CTLs in this group of 'grey zone' lymphomas. The patients included in this study were treated according to standard therapy protocols for HD and ALCL, respectively, so differences in clinical outcome within each subgroup cannot be accounted for by aberrant therapy protocols. However, the predictive value of percentage of activated CTLs should be confirmed in a prospective study in cases included in a clinical trial.
Our results seem to support the hypothesis that in some cases interaction between the cellular immune system and the tumor cells might be more relevant with regard to clinical outcome than established morphological and immunohistological criteria. That an interaction between the immune response and tumor cells does exist, has been shown by other groups demonstrating specific cytotoxic activity of CD8 + T cells against Hodgkin Reed-Sternberg cells of HD. 49, 50 It might be speculated that in cases with many activated CTLs, a selection of tumor cells has occurred that are resistant to both CTL-mediated and chemotherapy-mediated apoptosis. For instance, aberrant expression of the anti-apoptosis protein bcl-2, which reduces sensitivity to both chemotherapy and CTL-induced apoptosis, [51] [52] [53] [54] would explain why cases with a high percentage of activated CTLs are characterized by a shortened progression-free survival time, as well as poor overall survival. Thus far, we found upregulated expression of bcl-2 in tumor cells of cases with many activated CTLs, both in HD 55 and ALCL (unpublished data). Another mechanism whereby tumor cells might escape from CTL-mediated killing is expression of interleukin IL-10, which has direct suppressive effects on CTLs, 56, 57 and which has been shown to be expressed in both HD and ALCL. [58] [59] [60] However, this mechanism would not confer on tumor cells resistance to chemotherapy, and therefore would not explain our findings. We conclude that the percentage of activated CTLs present in tumor biopsies of classical HD and ALK negative ALCL patients is a strong prognostic marker, independent of histological diagnosis or clinical characteristics. As such it may be a helpful tool in determining therapeutic strategies in cases wherein the differentiation between ALK negative ALCL and HD remains difficult.
